How to buy Alimera Sciences stock

Alimera Sciences, Inc is a drug manufacturers-specialty & generic business based in the US. Alimera Sciences shares (ALIM) are listed on the NASDAQ and all prices are listed in US Dollars. Alimera Sciences employs 122 staff and has a trailing 12-month revenue of around USD$50.8 million.

How to buy shares in Alimera Sciences

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Alimera Sciences. Find the stock by name or ticker symbol: ALIM. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Alimera Sciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Alimera Sciences, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Alimera Sciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Alimera Sciences share price

Use our graph to track the performance of ALIM stocks over time.

Alimera Sciences shares at a glance

• Key figures

Information last updated 2021-03-03.

52-week range	USD$2.8602 - USD$10.79
50-day moving average	USD$7.8415
200-day moving average	USD$5.6487
Wall St. target price	USD$14.25
PE ratio	1.1297
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$0.303

Buy Alimera Sciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Alimera Sciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Alimera Sciences, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Alimera Sciences financials

Revenue TTM	USD$50.8 million
Gross profit TTM	USD$43.9 million
Return on assets TTM	-0.62%
Return on equity TTM	0%
Profit margin	-10.51%
Book value	$-0.479
Market capitalisation	USD$49 million

TTM: trailing 12 months

Shorting Alimera Sciences shares

There are currently 138,171 Alimera Sciences shares held short by investors – that's known as Alimera Sciences's "short interest". This figure is 1320.5% up from 9,727 last month.

There are a few different ways that this level of interest in shorting Alimera Sciences shares can be evaluated.

Alimera Sciences's "short interest ratio" (SIR)

Alimera Sciences's "short interest ratio" (SIR) is the quantity of Alimera Sciences shares currently shorted divided by the average quantity of Alimera Sciences shares traded daily (recently around 121202.63157895). Alimera Sciences's SIR currently stands at 1.14. In other words for every 100,000 Alimera Sciences shares traded daily on the market, roughly 1140 shares are currently held short.

However Alimera Sciences's short interest can also be evaluated against the total number of Alimera Sciences shares, or, against the total number of tradable Alimera Sciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Alimera Sciences's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Alimera Sciences shares in existence, roughly 20 shares are currently held short) or 0.0268% of the tradable shares (for every 100,000 tradable Alimera Sciences shares, roughly 27 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Alimera Sciences.

Find out more about how you can short Alimera Sciences stock.

Have Alimera Sciences's shares ever split?

Alimera Sciences's shares were split on a 1:15 basis on 15 November 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Alimera Sciences shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Alimera Sciences shares which in turn could have impacted Alimera Sciences's share price.

Alimera Sciences share price volatility

Over the last 12 months, Alimera Sciences's shares have ranged in value from as little as $2.8602 up to $10.79. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alimera Sciences's is 1.6387. This would suggest that Alimera Sciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Alimera Sciences overview

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. The company sells its products through direct sales and distributors to physician offices, pharmacies, and hospitals. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was founded in 2003 and is headquartered in Alpharetta, Georgia.

Frequently asked questions

• What percentage of Alimera Sciences is owned by insiders or institutions?

  Currently 16.349% of Alimera Sciences shares are held by insiders and 40.259% by institutions.

• How many people work for Alimera Sciences?

  Latest data suggests 122 work at Alimera Sciences.

• When does the fiscal year end for Alimera Sciences?

  Alimera Sciences's fiscal year ends in December.

• Where is Alimera Sciences based?

  Alimera Sciences's address is: 6120 Windward Parkway, Alpharetta, GA, United States, 30005

• What is Alimera Sciences's ISIN number?

  Alimera Sciences's international securities identification number is: US0162592028

• What is Alimera Sciences's CUSIP number?

  Alimera Sciences's Committee on Uniform Securities Identification Procedures number is: 016259103